Latest pharma news Archives - Page 10 of 10 - DelveInsight

Latest pharma news

Default Blog Image
Business Cocktail

Centrexion Therapeutics has raised a total of USD 67 million to fund phase 3 pain trial Jeffrey Kindler‘s managed biotech company Centrexion Therapeutics has raised $67 million. The funds will be ...


transthyretin amyloidosis
Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Ac...

Regeneron/Sanofi’s PD-1 drug candidate will be tested with ISA’s HPV immunotherapy Regeneron and Sanofi’s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma’s human papillomavirus (H...


BioGen
Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial

Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of th...


USFDA warns; Vit B3 prevents glaucoma; Zydus Cadila receives nod; U.S. experts soften on DNA editing

USFDA warns Bengaluru-based Resonance Labs of manufacturing norms violations US health regulator USFDA has red-flagged significant deviations from manufacturing norms at the Bengaluru-based API fac...


AstraZeneca announces; Trivitron launches; BrainStorm Cell Therapeutics validates

AstraZeneca announces availability of Saxa / Dapa FDC in UK UK-based AstraZeneca has announced the availability of Qtern for adult patients with type 2 diabetes in the country. Quern is a fixed dos...


Sanofi, Regeneron one step closer; Pharma’s deal; J&J and Actelion deal

Greek prosecutors raid Novartis offices, disclose wide-ranging probe into bribery allegations Greek officials announced that they are investigating Novartis for bribery in the wake of local media r...


Novartis Buys; FDA approves; Mayne Pharma Launches; Oxford Genetics Receives Grant

Novartis Buys Blood Disease Drug Maker for $665mn Novartis has acquired Selexys Pharmaceuticals, a drug maker specializing in development of therapeutics in certain hematologic and inflammatory dis...


Merck launches Biosimilars, ABITEC announces extension, First human clinical trial, FDA awards 2g...

Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community Merck has announced the launch of Biosimilars Clarified,...


Roche’s drug; Cancer drugs risk; FDA norms; Takeda sets deal

Roche's drug candidate for Multiple Sclerosis touted to be better than Merck’s Rebif The much anticipated multiple sclerosis drug from Roche, ocrelizumab, has overtaken Merck’s Rebif according to t...


Editor's Pick
Bone Metastasis Market: A Debilitating Consequence for Many Tumors

In advanced cancer patients, the most common site for the occurrence of metastasis is c...

Evaluating the Role of Digital Therapeutics as an Alternative to Conventional...

Depression is a mental condition characterized by prolonged series of poor moods, loss ...

Exploring the Market Potential of the Upcoming Therapies for the Myasthenia G...

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...

Scrutinizing the West Syndrome Market Space from Growth Perspectives

West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...

Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the...

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.